- Coordinator
- Universita Degli Studi Di Napoli Federico Ii, Italy
- Runs
- 1 February 2025 to 31 January 2029
- Status
- Running
- EU funding
- €3.5m
- Total cost
- —
- Partners
- 18 organisations in 8 countries
- Type
- Marie Skłodowska-Curie Action
- Grant agreement
- 101168287
What the project is doing
In the project's own words, from its summary on CORDIS.
The AUREUS doctoral network meets the increasing need of a highly qualified work force to counteract multidrug-resistant S. aureus infections by performing cutting-edge, inter-disciplinary research in the multifaceted field of chemical biology. The proposed research program aims at training Doctoral Candidates (DCs) to acquire complementary skills to exploit and develop different and innovative strategies to i) unveil the biosynthesis and structure of unique S. aureus cell wall glycopolymers, the so-called WTA (wall teichoic acids), ii) gain greater insights into the molecular basis of the human immune responses to S. aureus WTA, iii) harness the acquired knowledge to rationally design and develop effective immune-based therapies against S. aureus and related bacterial species.
To this end, the AUREUS intersectoral program is based on a unique international team combining expertise in different fields including chemistry, (micro-)biology and immunology. In detail, 9 world academic leaders in the glycoscience and/or S. aureus research world and 4 companies (SMEs) with world-class expertise in glycoscience, cutting-edge diagnostics and therapeutic research programs will be involved in the AUREUS project.
Each DC will have their own individual project, based on fundamental science and with practical applications, either in biotechnology or in biomedicine, as will be explored through secondments with our industrial partners. The AUREUS network will provide 14 young scientists with broad, top-class scientific and professional competences and skills, thereby expanding the pipeline of future leaders for both industry and academia.
Who is involved
| Organisation | City | Country | Role |
|---|---|---|---|
| Universita Degli Studi Di Napoli Federico Ii | Napoli | Italy | Coordinator |
| Universitat Wien | Wien | Austria | Participant |
| Eberhard Karls Universitaet Tuebingen | Tuebingen | Germany | Participant |
| Agencia Estatal Consejo Superior De Investigaciones Cientificas | Madrid | Spain | Participant |
| Universidad Autonoma De Madrid | Madrid | Spain | Associatedpartner |
| Glycodiag | Chevilly | France | Participant |
| Universite D'orleans | Orleans Cedex 2 | France | Associatedpartner |
| Universite Grenoble Alpes | Grenoble | France | Participant |
| National Institute for Bioprocessing Research and Training Limited | Blackrock Dublin | Ireland | Participant |
| University College Dublin, National University of Ireland, Dublin | Dublin | Ireland | Associatedpartner |
| Biopox SRL | Napoli | Italy | Associatedpartner |
| Innovation Acta SRL | Siena | Italy | Associatedpartner |
| Stichting Amsterdam Umc | Amsterdam | Netherlands | Participant |
| Universiteit Leiden | Leiden | Netherlands | Participant |
| Universiteit Van Amsterdam | Amsterdam | Netherlands | Associatedpartner |
| Iceni Glycoscience Limited | Colchester | United Kingdom | Associatedpartner |
| Imperial College of Science Technology and Medicine | London | United Kingdom | Associatedpartner |
| University of York | York North Yorkshire | United Kingdom | Associatedpartner |
Source: CORDIS, European Commission. Data of 5 Nov 2026, reused under the Commission's reuse policy. View on CORDIS · Grant DOI